William Blair analyst Matt Phipps has reiterated their bullish stance on AUTL stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Matt Phipps has given his Buy rating due to a combination of factors that highlight the potential of Autolus Therapeutics. The impressive sales figures for Aucatzyl, which surpassed both internal and consensus estimates, indicate a strong market presence in the treatment of adult relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Despite a temporary dip in stock value linked to uncertainties around the EU launch and changes in revenue recognition, the U.S. market remains a significant opportunity, with projections for substantial sales growth.
Furthermore, the differentiation of Aucatzyl in terms of safety and its early market share gains suggest a promising trajectory for Autolus. The company’s plans to expand into pediatric applications and other indications, such as autoimmune diseases, further bolster the potential for future growth. These factors contribute to an attractive valuation for Autolus shares, supporting the Buy rating despite short-term challenges.
In another report released today, Needham also reiterated a Buy rating on the stock with a $10.00 price target.